Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
Inquirer on MSN2d
Controlled drug Ketamine a lifeline for patients with severe depression in SingaporeSINGAPORE (The Straits Times/ANN): Ketamine, the controlled drug best known as a horse tranquilliser or party supplement, has ...
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback